Scribble

Price Momentum

MRNA is trading near the top of its 52-week range and above its 200-day simple moving average.
Price change

The price of MRNA shares has decreased $1.51 since the market last closed. This is a 1.08% drop.
Opened at $139.82.

The stock opened $0.51 lower than its previous close.

Key terms

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Market cap: $56.02B

A market capitalization between $10 billion and $200 billion places MRNA in the large capitalization category.

Key terms

Smart score

Yesterday 2:20pm ET Moderately bullish activity in Moderna with shares down 1.79% by TipRanks Yesterday 8:06am ET Merck price target raised to $170 from $146 at Guggenheim by TipRanks Sep 07, 2026 7:08am ET The Second Act of Biotech by TipRanks Sep 05, 2026 10:36am ET Cathie Wood Buys $3.6M of HOOD, Sells $2.9M of 2 High-Growth Stocks – September 5 by TipRanks Sep 04, 2026 2:20pm ET Buy/Sell: Wall Street’s top 10 stock calls this week by TipRanks Sep 03, 2026 2:50pm ET Cboe data shows mixed options sentiment in Moderna with shares down 3.87% by TipRanks Sep 03, 2026 11:51am ET Midday Fly By: Nvidia to acquire Hugging Face, Broadcom reports Q3 beat by TipRanks Sep 03, 2026 9:35am ET Broadcom upgraded, Ultragenyx downgraded: Wall Street’s top analyst calls by TipRanks Sep 03, 2026 8:55am ET Morning Movers: Victoria’s Secret, Campbell’s sink after quarterly earnings by TipRanks Sep 03, 2026 8:11am ET Moderna Stock (MRNA) Drops as Rothschild Downgrades to ‘Sell’ on Valuation Concerns by TipRanks Sep 03, 2026 5:20am ET Moderna downgraded to Sell from Neutral at Rothschild & Co Redburn by TipRanks Sep 01, 2026 5:22pm ET Moderna Raises $3 Billion via Convertible Notes Offering by TipRanks Aug 31, 2026 2:20pm ET Cboe data suggests bullish flow in Moderna with shares up 0.71% by TipRanks Aug 31, 2026 1:18pm ET Moderna Stock (MRNA) Was the Best Performer in August by TipRanks Aug 28, 2026 2:40pm ET Buy/Sell: Wall Street’s top 10 stock calls this week by TipRanks Aug 28, 2026 12:15pm ET BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why by TipRanks Aug 28, 2026 11:55am ET Midday Fly By: Stripe said to move on from PayPal pursuit by TipRanks Aug 28, 2026 10:55am ET mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley by TipRanks Aug 28, 2026 9:40am ET Moderna upgraded, Allstate downgraded: Wall Street’s top analyst calls by TipRanks Aug 28, 2026 7:45am ET Moderna upgraded to Buy at Argus after FDA approval for updated Covid vaccines by TipRanks Aug 28, 2026 7:35am ET Moderna prices upsized $2.6B offering of convertible senior notes due 2032 by TipRanks Aug 28, 2026 7:20am ET Moderna upgraded to Buy from Hold at Argus by TipRanks Aug 27, 2026 4:00pm ET Moderna receives FDA approval for updated 2026-2027 COVID-19 vaccines by TipRanks Aug 27, 2026 12:11pm ET Midday Fly By: Nvidia jumps on guidance, Salesforce reports beat and raise by TipRanks Aug 27, 2026 9:22am ET Moderna Stock (MRNA) Slides 3% on Plans for a $2B Private Placement by TipRanks Aug 27, 2026 9:00am ET Morning Movers: Dollar General surges following quarterly report by TipRanks Aug 27, 2026 7:35am ET Moderna down 6% to $141.10 after $2B convertible note offering by TipRanks Aug 27, 2026 7:25am ET Moderna to offer $2B of Convertible Senior Notes due 2032 by TipRanks Aug 26, 2026 3:40pm ET Cboe data shows mixed options sentiment in Moderna with shares down 7.64% by TipRanks Aug 25, 2026 12:10pm ET Midday Fly By: Dick’s reports downbeat Q2, United adds 10 new cities by TipRanks Aug 25, 2026 12:06pm ET Moderna rises 13.0% by TipRanks

1-year income & revenue

Total revenue: $1.94B (1Y), $145.00M (Q2)

Total Revenue decreased 39.93% since last year and decreased 62.72% since last quarter.
Net income: -$2.82B (1Y), -$782.00M (Q2)

Net Income increased 20.75% since last year and increased 41.77% since last quarter.
Earnings per share: -$7.25 (1Y), -$1.96 (Q2)

EPS increased 21.77% since last year and increased 42.21% since last quarter.

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

How competitors are chosen

MRNA's competitors are included in the Health Technology sector and Biotechnology group
Market cap: $56.02B

A market capitalization between $10 billion and $200 billion places MRNA in the large capitalization category.